Drug Characteristics
  • Formulation

    Tablets: 400mg

  • Dose

    Microsporidiosis : 400 mg orally twice a day for at least 3 weeks

    Strongyloides : 400 mg orally twice a day for 3 days followed by a repeated dose after 3 weeks if necessary        

  • Side Effects

    Reversible increases in LFTs, leukopenia, pancytopenia, gastrointestinal disturbances (abdominal pain, nausea and vomiting), headache, dizziness, alopecia, rash, fever

  • Interactions

    Albendazole is an inducer of cytochrome P450 isoenzymes, leading to possible reduced blood levels of other drugs metabolized via this route e.g. warfarin, oral contraceptives, protease inhibitors, NNRTIs etc.

  • Renal

    Dose as in normal renal function

  • Hepatic

    Although there are no current recommendations for dose reduction in patients with moderate to severe hepatic dysfunction, since albendazole undergoes nearly 100% first-pass metabolism via the liver all patients with raised LFTS and receiving extended courses of albendazole should be monitored for leukopenia and pancytopenia

  • Pregnancy

    Limited Human Data – Animal Data Suggest Moderate Risk

  • Other Information

    Poor oral bioavailability. Take with fatty food to maximise oral absorption.

    Unlicensed in UK, available from special order manufacturers.